Impact of ixekizumab treatment on depressive symptoms: An integrated analysis of three phase 3 clinical studies in patients with moderate-to-severe psoriasis - 21/04/16
Christopher Griffiths, Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester, United Kingdom; Maurizio Fava, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; Andrew Miller, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, United States; James Russell, Eli Lilly and Company, Indianapolis, IN, United States; Susan Ball, Eli Lilly and Company, Indianapolis, IN, United States; Isabel Xu, Eli Lilly and Company, Indianapolis, IN, United States; Nayan Acharya, Eli Lilly and Company, Indianapolis, IN, United States; Mark Rapaport, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, United States
Le texte complet de cet article est disponible en PDF. Supported by Eli Lilly and Company. |
Vol 74 - N° 5S1
P. AB253 - mai 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?